DBV Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
DBV Technologies presents preclinical data to support DBV`s EPITTM disease modifying effect
DBV Technologies SA:Presents preclinical data at the 2014 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting.Total of three oral and two poster presentations were communicated at congress.During a specific congress session, "AIT (Allergy Immunotherapy) mechanisms", Dr Vincent Dioszeghy, immunology researcher at DBV, showed the tropism for digestive system of EPIT-induced Tregs, which possess some homing receptors specific to gut.In second presentation, Dr Dioszeghy`s showed that therapeutic effect induced by EPIT was sustained even after discontinuation of epicutaneous immunotherapy.Dr Lucie Mondoulet`s study showed strong epigenetic modulation was observed during course of epicutaneous immunotherapy.Dr Lucie Mondoulet also described protective effect of treatment on subsequent sensitizations, thereby demonstrating the ability of EPIT to influence the course of allergic march.Dr Leticia Tordesillas compared the mechanism of action of DBV`s epicutaneous immunotherapy versus oral immunotherapy, showing that only protective effect of EPIT could prevent anaphylaxis after discontinuation of treatment.In Clinical & Experimental Allergy, publication of "The regulatory T cells induction by Epicutaneous immunotherapy is sustained and mediates long term protection from eosinophilic disorders in peanut sensitized mice" provides new data on Viaskin, highlighting its induction of regulatory T cells.
Latest Developments for DBV Technologies SA
- DBV Technologies announces publication on Epicutaneous Immunotherapy
- DBV Technologies announces proposed global offering for 2.67 mln shares
- DBV Technologies SA announces primary endpoint met in VIPES, Viaskin Peanut's Phase IIb clinical trial in peanut allergy
- DBV Technologies SA files IPO - Form F-1
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this